Salidroside Regulates Energy Metabolism Reprogramming to Suppress Tumor Proliferation: Mechanisms and Therapeutic Implications
- 1Department of Chinese Medicine, Beijing University of Chinese Medicine, Liangxiang Campus, Fangshan District, Beijing 102488, China
- 2School of Medicine, Xizang Minzu University, No.6, Wenhui East Road, Weicheng District, Xianyang 712082, China
Abstract
Salidroside, a phenylethanol glycoside and principal bioactive constituent of Rhodiola rosea, has emerged as a promising multi-target anti-tumor agent with significant effects on cancer energy metabolism. This review summarizes and analyzes the mechanisms it uses to reprogram tumor energy metabolism. Recent studies show that it upregulates the tumor suppressor miR-1343-3p in gastric cancer, which in turn targets two distinct metabolic axes: the OGDHL/PDHB–pyruvate axis, which impairs pyruvate oxidative decarboxylation and tricarboxylic acid cycle flux, and the ACOT11/FFA axis, which disrupts fatty acid hydrolysis and lipid-derived energy production. Both pathways are likely to converge at the reduction in acetyl-CoA, decreasing ATP synthesis and lowering the energy supply essential for rapid tumor proliferation. Furthermore, salidroside inhibits glycolysis through regulating STAT3/c-Myc, SLC7A11/cystine/GSH/GPX4, and PI3K/Akt/mTOR signaling pathways and sensitizes cancer cells to ferroptosis via regulating lipid metabolism and iron homeostasis. In vivo and in vitro studies indicate that salidroside possesses broad anti-tumor activity against a number of malignancies. This review synthesizes the findings from the past decade, providing a framework for understanding the multi-targeted inhibitory effects of salidroside on tumor metabolism and the challenges for clinical translation.
Related
- Wolbachia outcompetes mosquito-borne viruses by reprogramming host ATPSβ1-driven ATP metabolism toward symbiotic proliferation
- Salidroside inhibits glioma cell migration and proliferation through CYP2E1-neuroglobin-cytochrome c mediated redox axis
- Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications
- Macrophage lipid metabolism and inflammasome activation in rheumatoid arthritis: emerging mechanisms and therapeutic implications
- Metabolic reprogramming in macrophages: the central role of lipid metabolism in bone homeostasis.
BibTeX
@article{wang2026salidroside,
title = {{Salidroside Regulates Energy Metabolism Reprogramming to Suppress Tumor Proliferation: Mechanisms and Therapeutic Implications}},
author = {Haolin Wang and Yuxin Du},
journal = {Metabolites},
year = {2026},
month = oct,
doi = {10.3390/metabo16100748},
url = {https://www.mdpi.com/2218-1989/16/10/748},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Salidroside Regulates Energy Metabolism Reprogramming to Suppress Tumor Proliferation: Mechanisms and Therapeutic Implications
AU - Haolin Wang
AU - Yuxin Du
PY - 2026
DA - 2026/10/01
JO - Metabolites
DO - 10.3390/metabo16100748
UR - https://www.mdpi.com/2218-1989/16/10/748
AB - Salidroside, a phenylethanol glycoside and principal bioactive constituent of Rhodiola rosea, has emerged as a promising multi-target anti-tumor agent with significant effects on cancer energy metabolism. This review summarizes and analyzes the mechanisms it uses to reprogram tumor energy metabolism. Recent studies show that it upregulates the tumor suppressor miR-1343-3p in gastric cancer, which in turn targets two distinct metabolic axes: the OGDHL/PDHB–pyruvate axis, which impairs pyruvate oxidative decarboxylation and tricarboxylic acid cycle flux, and the ACOT11/FFA axis, which disrupts fatty acid hydrolysis and lipid-derived energy production. Both pathways are likely to converge at the reduction in acetyl-CoA, decreasing ATP synthesis and lowering the energy supply essential for rapid tumor proliferation. Furthermore, salidroside inhibits glycolysis through regulating STAT3/c-Myc, SLC7A11/cystine/GSH/GPX4, and PI3K/Akt/mTOR signaling pathways and sensitizes cancer cells to ferroptosis via regulating lipid metabolism and iron homeostasis. In vivo and in vitro studies indicate that salidroside possesses broad anti-tumor activity against a number of malignancies. This review synthesizes the findings from the past decade, providing a framework for understanding the multi-targeted inhibitory effects of salidroside on tumor metabolism and the challenges for clinical translation.
SN - 2218-1989
ER -